Pharmaceutical Biotechnology - Faculty for Chemistry and Pharmacy
Pharmaceutical Biotechnology - Faculty for Chemistry and Pharmacy
| 1983 | Diploma (Dipl.Ing.) in Chemistry/Biochemistry; Technical University of Vienna |
| 1985 | Ph. D. (Dr. tech.) in Organic Chemistry; Technical University of Vienna |
| 1994 | Habilitation (Doz.) in Biochemistry; University of Vienna, Medical Faculty |
| 1985-1987 | Postdoc and Scientist at the Federal School of Technology (ETH) Zurich, Switzerland; working on sugar phosphates and origin-of-life chemistry (prebiotic formation of nucleic acid precursors). |
| 1988-1995 | Group leader, Institute of Molecular Pathology, Vienna, Austria; working on receptor-mediated gene delivery, artificial virus-like gene transfer systems. |
| 1996 | Professor Biopharmaceutical Sciences, Utrecht University, The Netherlands. |
| 1992-2001 | Director Cancer Vaccines & Gene Therapy, Boehringer Ingelheim Austria; research, development and production of gene-modified cancer vaccines (clinical trials in Austria and Germany started in 1994 and 1998). |
| 1995-2002 | Group leader, at the Institute of Biochemistry, Vienna University Biocenter; working on synthetic virus-like gene transfer systems. |
| Since 2001 | Full Professor (C4) for Pharmaceutical Biology - Biotechnology, LMU Munich, Germany. |
| Since 2005 | Member of Munich Center of Nanoscience (CeNS) |
| 2006-2008 | Director, Department of Pharmacy |
| 2007-2010 | Coordinator of Area "Programmed Drug Delivery" within the DFG Excellence Cluster “Nanosystems Initiative Munich (NIM)” |
| 2010-2019 | Area Coordinator of “Biomedical Nanotechnologies” and Executive Board Member of “Nanosystems Initiative Munich (NIM)” |
| 2012-2013 | Visiting Professor (Senior Scholar) Fudan University, Shanghai |
| 2016-2018 | Deputy Director, Department of Pharmacy |
| 2018-2020 | Director, Department of Pharmacy |
|
≥ 511 publications, ≥ 20 patents, ≥ 315 international lectures, > 51 944 citations on GS, h-index 113 |
| 1995-2003 | Scientific panel for Gene Therapy and Gene Analysis of the Austrian Federal commission for Gene Technology |
| 1996-2003 | DECHEMA Arbeitsgruppe Medizinische Biotechnologie |
| 1997-2000 | Gene Therapy Committee, American Society for Gene Therapy |
| 1998-2001 | European Gene Therapy Working group EFPIA |
| 2001-2002 | European Society for Gene Therapy, Committee nonviral vectors |
| Since 2004 | Member of EUFEPS Committee for Academic Research |
| Since 2005 | Member of Center of Nanoscience (CeNS, Munich) |
| 2007-2010 | Nonviral Vector Committee, ASGT, American Society for Gene Therapy |
| Since 2007 | Deutsche Gesellschaft für Gentherapie (DG-GT), Beirat, physicochemical vectors |
| Since 2010 | European Society for Gene and Cell Therapy, Committee nonviral vectors |
| 2012-2016 | Physical Gene & Cell Therapy and Vectorology Committee, ASGCT |
| 2015-2016 | Chair of Physical Gene & Cell Therapy and Vectorology Committee, ASGCT (now: Physical Delivery Therapeutics & Vector Development Committee) |
| 2014-2017 | Chemical Gene & Cell Therapy Committee, ASGCT (now: Nanoagents & Synthetic Formulations Committee) |
| Since 2018 | European Academy of Sciences (EurASc), Officer, Devision Medicine and Life Sciences |
| 2022-2025 | Nonviral Therapeutic Delivery Committee, ASGCT |